摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[4-(4-溴吡唑-1-基)-哌啶-1-基]-乙酮 | 1092500-88-3

中文名称
1-[4-(4-溴吡唑-1-基)-哌啶-1-基]-乙酮
中文别名
——
英文名称
1-[4-(4-bromo-pyrazol-1-yl)-piperidin-1-yl]-ethanone
英文别名
1-(4-(4-bromo-1H-pyrazol-1-yl)piperidin-1-yl)ethanone;1-[4-(4-bromopyrazol-1-yl)piperidin-1-yl]ethanone
1-[4-(4-溴吡唑-1-基)-哌啶-1-基]-乙酮化学式
CAS
1092500-88-3
化学式
C10H14BrN3O
mdl
——
分子量
272.145
InChiKey
JNNNSSGQNKRDFS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    38.1
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Compounds And Compositions for the Treatment of Ocular Disorders
    申请人:Graybug Vision, Inc.
    公开号:US20170080092A1
    公开(公告)日:2017-03-23
    The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
    该披露描述了前药和前列腺素的衍生物、碳酸酐酶抑制剂、激酶抑制剂、β-肾上腺素受体拮抗剂和其他药物,以及含有这些前药和衍生物的受控释放配方,用于治疗眼部疾病。
  • [EN] PYRAZOLE-SUBSTITUTED AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSES AMINOHETEROARYLE A SUBSTITUTION PYRAZOLE SERVANT D'INHIBITEURS DE PROTEINE KINASE
    申请人:PFIZER
    公开号:WO2006021881A2
    公开(公告)日:2006-03-02
    Compounds of formula (1) are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.
    提供了化学式(1)的化合物,以及它们的合成和使用方法。优选的化合物是c-Met蛋白激酶的有效抑制剂,并可用于治疗异常细胞生长障碍,如癌症。
  • Quinoxaline derivatives as tyrosine kinase activity inhibitors
    申请人:Novartis AG
    公开号:US08193189B2
    公开(公告)日:2012-06-05
    The present invention relates to quinoxaline compound of the formula (I): wherein R1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R7; R2 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R8; R3, R4, R5 and R6 are each independently hydrogen or R9; and R7, R8 and R9 are each independently selected from organic and inorganic substituents, their use in therapy of diseases, in particular diseases mediated by the tyrosine kinase activity of Janus kinases, including JAK-2 and JAK-3 kinases.
    本发明涉及公式(I)的喹喔啉化合物:其中,R1是碳环或杂环,其中任意一个可以用1、2、3、4或5个R7取代;R2是碳环或杂环,其中任意一个可以用1、2、3、4或5个R8取代;R3、R4、R5和R6各自独立地是氢或R9;而R7、R8和R9各自独立地选自有机和无机取代基,它们用于治疗疾病,特别是由Janus激酶的酪氨酸激酶活性介导的疾病,包括JAK-2和JAK-3激酶。
  • Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors
    申请人:Gerspacher Marc
    公开号:US20100168062A1
    公开(公告)日:2010-07-01
    The present invention relates to quinoxaline compound of the formula (I): wherein R 1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R 7 ; R 2 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R 8 ; R 3 , R 4 , R 5 and R 8 are each independently hydrogen or R 9 ; and R 7 , R 8 and R 9 are each independently selected from organic and inorganic substituents, their use in therapy of diseases, in particular diseases mediated by the tyrosine kinase activity of Janus kinases, including JAK-2 and JAK-3 kinases.
    本发明涉及式(I)的喹喔啉化合物:其中R1是碳环或杂环,其中任一可以用1、2、3、4或5个R7取代; R2是碳环或杂环,其中任一可以用1、2、3、4或5个R8取代; R3、R4、R5和R8各自独立地是氢或R9; 而R7、R8和R9各自独立地选自有机和无机取代基,在治疗疾病中的应用,特别是由Janus激酶的酪氨酸激酶活性介导的疾病,包括JAK-2和JAK-3激酶。
  • IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES
    申请人:Berdini Valerio
    公开号:US20120208791A1
    公开(公告)日:2012-08-16
    The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    本发明涉及新的双环杂环衍生物化合物,涉及包含该化合物的药物组合物以及涉及使用该化合物治疗疾病,例如癌症的用途。
查看更多